Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Bryhali

Phase 3Small molecule

IIcahn School of Medicine at Mount Sinai

Bryhali is one of 27 small molecule programs targeting Keloid. It is currently in Phase 3.

1

Indications

1

Total Trials

0

Active Trials

26

Competitors

Pipeline

Status by Indication[3][1]

Indication

KeloidActive, not recruiting

KeloidPhase 3

Active, not recruiting

Competition

Competitive Landscape

63 competitors in Keloid

#DrugCompanyPhaseTrials

Blenoxane

Bristol-Myers Squibb

Kenalog

BBassett Healthcare

Botox

RRevance Therapeutics, Inc.

Calan

Decadron

AAspen Global Incorporated

Esbriet

LLegacy Health System

Nexavar

Opzelura

Avastin

BBio-Thera Solutions

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Keloid1 trial

Duobrii Treatment of Acne Keloidalis Nuchae (AKN)

Terminated·IIcahn School of Medicine at Mount Sinai·Phase 3·NCT05608499·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bryhali. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bryhali compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bryhali. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Icahn School of Medicine at Mount Sinai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IIcahn School of Medicine at Mount Sinai

Related News